Clinical Trial of TN-401 Gene Therapy for the Potential Treatment of PKP2-Associated Arrhythmogenic Right Ventricular ...

Chief Executive Officer of Tenaya Therapeutics. "Funds from this grant will support our ongoing RIDGE-1 clinical trial of TN-401, a potential best-in-class gene therapy for the treatment of PKP2 ...

Hercules Capital brings a conservative yet flexible BDC strategy and a focus on innovative companies. Read why dividend ...

Chief Executive Officer of Tenaya. “As we enter 2025, we are eager to build on this momentum to accelerate enrollment and report on safety, biopsy and initial clinical endpoints from both our TN ...

Amid these developments, Tenaya announced the departure of Leone Patterson, its Chief Financial and Business Officer, and is currently seeking a replacement. Despite this, analyst firms such as H ...

South San Francisco, CA, January 30, 2025 – The California Institute for Regenerative Medicine (CIRM), one of the world’s largest institutions dedicated to regenerative medicine, has awarded nearly ...

In a move to motivate and retain its employees, Tenaya Therapeutics , Inc. (NASDAQ:TNYA), a biotechnology firm specializing in biological products, has announced the repricing of certain stock options ...

“2024 was a pivotal year for Tenaya, marked by important operational execution across our clinical-stage pipeline of gene therapy candidates with the potential to target and address the underlying ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema ...